Johnson & Johnson (NYSE:JNJ) Given New $225.00 Price Target at Sanford C. Bernstein

Johnson & Johnson (NYSE:JNJ) had its price target upped by Sanford C. Bernstein from $208.00 to $225.00 in a report published on Friday,MarketScreener reports. The firm currently has a market perform rating on the stock.

Several other equities research analysts also recently weighed in on the stock. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a research note on Monday, October 20th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Freedom Capital lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Bank of America upped their price target on Johnson & Johnson from $220.00 to $221.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, Wolfe Research lifted their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $224.82.

Johnson & Johnson Trading Up 0.8%

Shares of NYSE JNJ opened at $220.29 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $530.74 billion, a PE ratio of 19.94, a PEG ratio of 2.24 and a beta of 0.34. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $222.17. The stock has a fifty day simple moving average of $208.35 and a 200-day simple moving average of $188.93.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, meeting analysts’ consensus estimates of $2.46. The company had revenue of $24.56 billion during the quarter, compared to analysts’ expectations of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.Johnson & Johnson’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period last year, the business posted $2.04 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Institutional Trading of Johnson & Johnson

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JNJ. Bingham Private Wealth LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth about $1,785,000. Farther Finance Advisors LLC increased its position in Johnson & Johnson by 28.4% during the fourth quarter. Farther Finance Advisors LLC now owns 106,454 shares of the company’s stock worth $22,031,000 after buying an additional 23,522 shares during the period. Warburton Capital Management LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $218,000. ZWJ Investment Counsel Inc. boosted its holdings in shares of Johnson & Johnson by 1.3% in the fourth quarter. ZWJ Investment Counsel Inc. now owns 216,865 shares of the company’s stock valued at $44,880,000 after acquiring an additional 2,764 shares during the period. Finally, R. W. Roge & Company Inc. grew its position in shares of Johnson & Johnson by 7.9% during the fourth quarter. R. W. Roge & Company Inc. now owns 1,556 shares of the company’s stock worth $321,000 after acquiring an additional 114 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 beat, stronger guidance and rising free cash flow: JNJ beat Q4 revenue and EPS expectations, raised FY outlook and guided to materially higher 2026 free cash flow (~$21B), which underpins analyst upgrades and ETF buying interest. ETFs to Buy Post JNJ’s Q4 Earnings Surprise & Bullish Cash Flow View
• Positive Sentiment: Large Scotiabank upgrade: Scotiabank moved to “sector outperform” and raised its target sharply (to $265), signaling confidence in J&J’s growth runway and boosting investor appetite. Johnson & Johnson (JNJ) Gets a Buy from Scotiabank
• Positive Sentiment: Multiple price target raises from analysts: Leerink (+$201→$232) and Sanford C. Bernstein (+$208→$225) (and others including Stifel, BofA) have nudged targets higher, reflecting the quarter and helping push sentiment positive. Leerink Raises Price Target Bernstein Raises Price Target
• Positive Sentiment: Technical/trend signals: MarketBeat highlights a trend‑following buy signal after a post‑earnings pullback — technical confirmation can attract momentum and institutional flows. Trend‑Following Buy Signal
• Positive Sentiment: MedTech strength and product pipeline: MedTech sales growth, product launches and the OTTAVA robotic submission provide a potential high‑growth stream beyond staples like Stelara. MedTech Growth & Product Launches
• Neutral Sentiment: Valuation checks: Coverage pieces are assessing JNJ’s valuation after the rally — some see limited near‑term upside from current levels, which could temper aggressive buying. Valuation After Momentum
• Negative Sentiment: Talc litigation risk: A Special Master allowed plaintiffs’ expert testimony in the talc MDL, keeping litigation risk visible and a potential earnings/cash‑flow overhang. Talc Litigation Update

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.